Siage Biopharma

Siage Biopharma (Hangzhou Siage Biopharma Co., Ltd.) is a high-growth Chinese biotechnology company specializing in high-throughput in vitro diagnostics (IVD). Founded in 2016 by former BD Biosciences executive Feng Xu, the company focuses on the development and commercialization of multiplexed cytokine and biomarker detection kits using its proprietary flow fluorescence (liquid chip) platform. Their product portfolio is designed for precision monitoring of systemic inflammation, sepsis, and cancer, with an emerging focus on blood-based diagnostics for neurodegenerative conditions like Alzheimer’s disease. Siage Biopharma has established itself as a leading innovator in the Chinese life sciences tools and diagnostics sector, supported by top-tier venture capital investors.